Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario - Wikidata - awgldk - TriplyDB

Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario

Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario

http://www.wikidata.org/entity/Q33611088

about

Implementation of precision medicine in clinical trials in thoracic oncology: Which are the hurdles?Personalized medicine for non-small cell lung cancer: where are we now and where can we go?Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective

P2860

Q48325576-D2C11069-5726-431B-9009-FAE20F75C6A8 Q49545117-2A50233B-0E19-477B-B463-E8FA90A4A740 Q57177486-3F9DA2E0-8479-4533-ABCC-FD0E563E41ED

P2860

Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario

http://www.wikidata.org/entity/Q33611088

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Improving molecular testing an ...... ll-cell lung cancer in Ontario

@ast

Improving molecular testing an ...... ll-cell lung cancer in Ontario

@en

type

label

Improving molecular testing an ...... ll-cell lung cancer in Ontario

@ast

Improving molecular testing an ...... ll-cell lung cancer in Ontario

@en

prefLabel

Improving molecular testing an ...... ll-cell lung cancer in Ontario

@ast

Improving molecular testing an ...... ll-cell lung cancer in Ontario

@en

P1433

Q33611088-830E6D94-604C-4F2D-B1AA-F8419FA2D9F0

P1476

Q33611088-A4703DB2-E676-4076-BCCB-500E5C59EB80

P2093

Q33611088-054BCA54-0CDF-4189-84A8-A553FD1E88EF

Q33611088-073CDEE9-7182-42F0-B5B1-4401A2824345

Q33611088-1828BD65-3612-40C2-88EB-537203C7B9EE

Q33611088-1B675998-8343-4E79-9D62-B72D5E77206A

Q33611088-2FC235C5-4A29-47E7-B85E-E2372FB59213

Q33611088-354457AF-D6F3-40A5-B89A-673F0B7365EF

Q33611088-434F2867-C88E-4EE2-9B0C-18932250A586

Q33611088-50042FF8-6645-409F-ADC4-829531DB2A5A

Q33611088-5220E446-DC0A-4946-B9B8-701C6EAD8FA2

Q33611088-7CF2451D-9C4A-4A89-BF04-F03AF8870173

P2860

Q33611088-058B12AA-2EEE-4FEB-A712-D09974CEE6C0

Q33611088-0D3EE00A-8F57-46D3-9FA1-B6B6A1A338F1

Q33611088-0E461553-793E-46A4-9D2A-9F8DAA00503B

Q33611088-200A6A67-57D0-4E4E-926D-334207523B6B

Q33611088-20294F06-AB46-4143-AF1D-19B98DCA2D02

Q33611088-2F81C91D-2E3B-4C8D-BA44-B2A1AA93481F

Q33611088-32B76E25-F257-4D2E-A260-81F302A86CAF

Q33611088-395C3312-3F10-4CD7-AD77-7C757ADC099F

Q33611088-3F233587-8B8D-4422-9AB6-FCD4CEBED9D3

Q33611088-437B3197-DE67-49D0-9793-F67C6C43A5C5

P304

Q33611088-B24E9E3E-C334-4531-82EC-8388CFEAD1F5

P31

Q33611088-12BCAD67-79FF-4BAA-BEFE-75BCF2B728D3

P356

Q33611088-1B611469-78DE-439D-90B9-7E86DA262A80

P433

Q33611088-E89C9404-2E93-41F4-BCE7-8B385F5BDD77

P478

Q33611088-F5192A24-714A-4EE6-AC94-63333EDFF8D0

P50

Q33611088-39B2AE7D-420F-4CA0-97B6-B6C80C11C79C

Q33611088-3E7BB2C5-E1E2-468B-9B28-2BC032D9B0E2

P577

Q33611088-EEF29691-8072-4866-8F3D-A9CC1037DF6C

P698

Q33611088-7EE55A46-F564-4518-ACD7-99AE3DBF373F

P932

Q33611088-3B9A8040-72D8-4DD4-8C0B-ED4BCA1C251F

P356

P1433

Current Oncology

P1476

Improving molecular testing an ...... ll-cell lung cancer in Ontario

@en

P2093

A Brade

http://www.w3.org/2001/XMLSchema#string

C Lim

http://www.w3.org/2001/XMLSchema#string

C Sit

http://www.w3.org/2001/XMLSchema#string

D M Hwang

http://www.w3.org/2001/XMLSchema#string

G da Cunha Santos

http://www.w3.org/2001/XMLSchema#string

H S Sekhon

http://www.w3.org/2001/XMLSchema#string

J C Cutz

http://www.w3.org/2001/XMLSchema#string

M Binnie

http://www.w3.org/2001/XMLSchema#string

M Patel

http://www.w3.org/2001/XMLSchema#string

N B Leighl

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Guideline for the acquisition and preparation of conventional and endobronchial ultrasound-guided transbronchial needle aspiration specimens for the diagnosis and molecular testing of patients with known or suspected lung cancer

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Pembrolizumab for the treatment of non-small-cell lung cancer

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study

P304

103-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.24.3495

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Suzanne Kamel-Reid

Ming-Sound Tsao

P577

2017-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28490924

http://www.w3.org/2001/XMLSchema#string

P932

5407861

http://www.w3.org/2001/XMLSchema#string